Literature DB >> 9276535

Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals.

S R Thurau1, C C Chan, R B Nussenblatt, R R Caspi.   

Abstract

Oral administration of uveitogenic retinal antigens suppresses the expression of EAU induced by a subsequent immunization with these antigens. Effectiveness and mechanisms of oral tolerance in EAU have mainly been studied in the acute, monophasic model in Lewis rats by feeding antigen prior to induction of disease. In this study we investigated the effect of oral tolerance induction in the acute as well as the chronic-relapsing models in the B10.A mouse. In acute murine EAU we could effectively suppress disease by induction of oral tolerance prior to immunization. In the chronic-relapsing EAU, antigen feeding was started only after the animals had recovered from their first attack of uveitis. Under these experimental conditions the subsequent relapse was largely prevented. These experiments demonstrate that oral tolerance may have practical clinical implications in uveitis, which is predominantly a chronic-relapsing condition in humans.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9276535      PMCID: PMC1904752          DOI: 10.1046/j.1365-2249.1997.4571356.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  52 in total

1.  Single dose intranasal administration of retinal autoantigen generates a rapid accumulation and cell activation in draining lymph node and spleen: implications for tolerance therapy.

Authors:  A D Dick; V Sharma; J Liversidge
Journal:  Br J Ophthalmol       Date:  2001-08       Impact factor: 4.638

2.  Anti-inflammatory or proinflammatory effect of an adenosine receptor agonist on the Th17 autoimmune response is inflammatory environment-dependent.

Authors:  Dongchun Liang; Aijun Zuo; Hui Shao; Mingjiazi Chen; Henry J Kaplan; Deming Sun
Journal:  J Immunol       Date:  2014-11-03       Impact factor: 5.422

3.  Characterization of autoreactive and bystander IL-17+ T cells induced in immunized C57BL/6 mice.

Authors:  Hong Nian; Dongchun Liang; Aijun Zuo; Ruihua Wei; Hui Shao; Willi K Born; Henry J Kaplan; Deming Sun
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-21       Impact factor: 4.799

4.  Regulatory effect of gammadelta T cells on IL-17+ uveitogenic T cells.

Authors:  Hong Nian; Hui Shao; Guoming Zhang; Willi K Born; Rebecca L O'Brien; Henry J Kaplan; Deming Sun
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-07       Impact factor: 4.799

5.  In vivo priming of IL-17(+) uveitogenic T cells is enhanced by Toll ligand receptor (TLR)2 and TLR4 agonists via γδ T cell activation.

Authors:  Aijun Zuo; Dongchun Liang; Hui Shao; Willi K Born; Henry J Kaplan; Deming Sun
Journal:  Mol Immunol       Date:  2012-02-01       Impact factor: 4.407

6.  Supplementation of CD4+CD25+ regulatory T cells suppresses experimental autoimmune uveoretinitis.

Authors:  H Keino; M Takeuchi; Y Usui; T Hattori; N Yamakawa; T Kezuka; J-I Sakai; M Usui
Journal:  Br J Ophthalmol       Date:  2006-08-30       Impact factor: 4.638

7.  Oral administration of Alequel, a mixture of autologous colon-extracted proteins for the treatment of Crohn's disease.

Authors:  Eran Israeli; Yaron Ilan
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

8.  Continuous nasal administration of antigen is critical to maintain tolerance in adoptively transferred autoimmune arthritis in SCID mice.

Authors:  T Bárdos; M Czipri; C Vermes; J Zhang; K Mikecz; T T Glant
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

9.  Anti-inflammatory role of IL-17 in experimental autoimmune uveitis.

Authors:  Yan Ke; Ke Liu; Guo-Qiang Huang; Yan Cui; Henry J Kaplan; Hui Shao; Deming Sun
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

10.  Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.

Authors:  D A Copland; K Hussain; S Baalasubramanian; T R Hughes; B P Morgan; H Xu; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.